In this interview, take a look behind the scenes of a recent Future Microbiology paper on antibiotic resistance targets for point-of-care diagnostics with author, John P. Hays.
In this interview, we speak to Ana Litvintseva, a Medical Mycologist and Team Lead at the Centers for Disease Control and Prevention (CDC; GA, USA) about Candida auris, its emergence and the challenges it presents.
Since Zika broke into the news in 2016, new research has been uncovering more information about this virus – we spoke to Dustin Farr at the recent ASM Microbe meeting where he was presenting a poster on Zika infection in corneal cells.
We speak to infectious diseases specialist, Ellie Goldstein (Santa Monica, CA, USA), about his recent publication on real world data and the challenges facing drug-resistant infections.
In line with our July focus around enteric infections, we recently spoke to Christina Faherty and Research Fellow from her lab, Alejandro Llanos-Chea, about the lab’s research on Shigella, Salmonella and E. coli and novel models for these in vitro.
Guy Thwaites, Director of the Oxford University Clinical Research Unit/Wellcome Program in Vietnam, speaks on neurotuberculosis and the challenges it faces in terms of treatment, HIV co-infection and the political will necessary for change.
In this interview, take a look behind the scenes of a recent Future Microbiology paper on the role of transition metal control in E. coli virulence with author, Jeffrey Henderson.
Take a look behind the scenes of a recent Future Virology article entitled ‘Latent vs productive infections: The alpha herpesvirus switch’ as we ask authors Lynn Enquist, Orkide Koyuncu and Margaret MacGibeny about latency, reactivation and the best models.
In this interview we take a look at cholera outbreak situations and the strategies required to tackle them as we talk to Martin Mengel following his presentation at ECCMID.
Take a look behind the scenes of a recent Future Virology review entitled ‘Antiviral therapeutic approaches for human rhinovirus infections’ as we ask author Peter Barlow about antivirals, antibodies and the host response.